Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: Role in regulation of myeloma cell proliferation

Leukemia

Volumn 26, Issue 10, 2012, Pages 2286-2296

  Arendt, B K ^a   Walters, D K ^a   Wu, X ^a   Tschumper, R C ^a   Huddleston, P M ^a   Henderson, K J ^a   Dispenzieri, A ^a   Jelinek, D F ^a  

^a MAYO CLINIC   (United States)

Author keywords

CD147; Cyclophilin B; Multiple myeloma; Plasma cells

Indexed keywords

CD147 ANTIGEN; CYCLOPHILIN B;

ARTICLE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIGENS, CD147; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPHILINS; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA;

EID: 84867405610     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.91     Document Type: Article

References (53)

1. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417
2. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5422.
3. International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
4. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 573-589. (Pubitemid 44255500)
5. Kyle RA. 'Benign' monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68: 26-36. (Pubitemid 23018154)
6. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
7. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149: 334-351.
8. Iacono KT, Brown AL, Greene MI, Saouaf SJ. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 2007; 83: 283-295. (Pubitemid 350087035)
9. Yurchenko V, Constant S, Eisenmesser E, Bukrinsky M. Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Clin Exp Immunol 2010; 160: 305-317.
10. Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L et al. HAb18G (CD147), a cancerassociated biomarker and its role in cancer detection. Histopathology 2009; 54: 677-687.
11. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997; 151: 665-670. (Pubitemid 27385597)
12. Zheng HC, Takahashi H, Murai Y, Cui ZG, Nomoto K, Miwa S et al. Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer 2006; 95: 1371-1378. (Pubitemid 44760088)
13. Kanekura T, Chen X. CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 2010; 57: 149-154.
14. Nawroth R, Stohr R, Hartmann A, Gschwend JE, Retz M. EMMPRIN (CD147). A new key protein during tumor progression in bladder cancer. Urologe A 2008; 47: 1152-1156.
15. Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 2005; 93: 199-204. (Pubitemid 40253722)
16. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005; 65: 3193-3199. (Pubitemid 40524601)
17. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001; 61: 2276-2281. (Pubitemid 32692059)
18. Yang JM, O'Neill P, Jin W, Foty R, Medina DJ, Xu Z et al. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J Biol Chem 2006; 281: 9719-9727. (Pubitemid 43864690)
19. Yurchenko V, O'Connor M, Dai WW, Guo H, Toole B, Sherry B et al. CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun 2001; 288: 786-788. (Pubitemid 33140950)
20. Yurchenko V, Zybarth G, O'Connor M, Dai WW, Franchin G, Hao T et al. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 2002; 277: 22959-22965. (Pubitemid 34967280)
21. Pakula R, Melchior A, Denys A, Vanpouille C, Mazurier J, Allain F. Syndecan-1/CD147 association is essential for cyclophilin B-induced activation of p44/42 mitogen-activated protein kinases and promotion of cell adhesion and chemotaxis. Glycobiology 2007; 17: 492-503. (Pubitemid 47049937)
22. Allain F, Vanpouille C, Carpentier M, Slomianny MC, Durieux S, Spik G. Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc Natl Acad Sci USA 2002; 99: 2714-2719. (Pubitemid 34240526)
23. Bauer K, Kretzschmar AK, Cvijic H, Blumert C, Loffler D, Brocke-Heidrich K et al. Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells. Oncogene 2009; 28: 2784-2795.
24. Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA et al. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res 1993; 53: 5320-5327. (Pubitemid 23333406)
25. Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 2008; 112: 1931-1941.
26. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996; 10: 866-876. (Pubitemid 26168407)
27. Walters DK, Wu X, Tschumper RC, Arendt BK, Huddleston PM, Henderson KJ et al. Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia 2011; 25: 1344-1353.
28. Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS et al. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clin Invest 2008; 118: 306-315.
29. Walters DK, Jelinek DF. The effectiveness of double-stranded short inhibitory RNAs (siRNAs) may depend on the method of transfection. Antisense Nucleic Acid Drug Dev 2002; 12: 411-418. (Pubitemid 36169199)
30. Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell 2004; 15: 4043-4050. (Pubitemid 39122010)
31. Tang W, Hemler ME. Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering. J Biol Chem 2004; 279: 11112-11118. (Pubitemid 38401604)
32. Voigt H, Vetter-Kauczok CS, Schrama D, Hofmann UB, Becker JC, Houben R. CD147 impacts angiogenesis and metastasis formation. Cancer Invest 2009; 27: 329-333.
33. Xu J, Xu HY, Zhang Q, Song F, Jiang JL, Yang XM et al. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 2007; 5: 605-614. (Pubitemid 46985049)
34. Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005; 105: 4845-4848. (Pubitemid 40807312)
35. Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S et al. Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem 1999; 47: 1575-1580.
36. Muraoka K, Nabeshima K, Murayama T, Biswas C, Koono M. Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers. Int J Cancer 1993; 55: 19-26. (Pubitemid 23261700)
37. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 2006; 56: 359-367. (Pubitemid 43886799)
38. Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 2001; 97: 2522-2523. (Pubitemid 32291501)
39. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387. (Pubitemid 23172924)
40. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 2005; 19: 1466-1470. (Pubitemid 41136343)
41. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004; 89: 547-551. (Pubitemid 38691241)
42. Menke DM, Horny HP, Griesser H, Atkinson EJ, Kaiserling E, Kyle RA. Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1). J Clin Pathol 1998; 51: 432-437. (Pubitemid 28312174)
43. Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutierrez N et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26: 2737-2744.
44. Yang Y, Lu N, Zhou J, Chen ZN, Zhu P. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 1299-1310.
45. Yurchenko V, Constant S, Bukrinsky M. Dealing with the family: CD147 interactions with cyclophilins. Immunology 2006; 117: 301-309.
46. Li M, Zhai Q, Bharadwaj U, Wang H, Li F, Fisher WE et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006; 106: 2284-2294. (Pubitemid 43673252)
47. Baba M, Inoue M, Itoh K, Nishizawa Y. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem Biophys Res Commun 2008; 374: 111-116.
48. Chen X, Lin J, Kanekura T, Su J, Lin W, Xie H et al. A small interfering CD147- targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res 2006; 66: 11323-11330. (Pubitemid 46009963)
49. Chen X, Su J, Chang J, Kanekura T, Li J, Kuang YH et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell proliferation, activation, adhesion, and migration activity in the human Jurkat T-lymphoma cell line. Cancer Invest 2008; 26: 689-697.
50. Wang B, Xu YF, He BS, Pan YQ, Zhang LR, Zhu C et al. RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro. J Exp Clin Cancer Res 2010; 29: 61.
51. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210-2216. (Pubitemid 34753592)
52. Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999; 79: 451-455. (Pubitemid 29046218)
53. Kelly T, Borset M, Abe E, Gaddy-Kurten D, Sanderson RD. Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma 2000; 37: 273-281. (Pubitemid 30162538)